Yes, that is a long headline is it not?
PharmaTimes and others cover a paper in PloS Medicine authored by a number of medicines regulators including the European Medicines Agency (EMA), calling for openness in raw trial data. The three pronged approach they suggest looks like a good basis for discussion. It would be interesting to know whether patient groups or charities have made any response to their suggestions.
Meanwhile, the European Patients’ Academy on Therapuetic Innovation (EUPATI) has issued a call for examples of educational materials on medicines development. EUPATI is a new initiative launched earlier this year to improve patient-facing materials on medicines R&D.